Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Arrowhead Pharmaceuticals yesterday and set a price target of $81.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jason Gerberry has given his Buy rating due to a combination of factors tied mainly to Arrowhead’s APOC3 opportunity and the market setup. He argues that the recent weakness in ARWR shares, driven by concerns over a competitor’s INHBE data, already reflects much of the perceived obesity risk, while the core driver remains the upcoming Phase 3 Shasta-3/4 readouts in severe hypertriglyceridemia and associated value unlock.
Gerberry modestly trims his probability of success for Arrowhead’s obesity-related INHBE/ALK7 programs, which reduces his price objective only slightly to $81 from $84, but he maintains that these assets are incremental to the main APOC3 story. He expects Arrowhead and Ionis to effectively share the severe hypertriglyceridemia market and views recent competitor pricing developments as expanding the revenue potential, supporting a favorable risk‑reward and reinforcing his Buy recommendation despite class-level uncertainties in obesity mechanisms.
Gerberry covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Ionis Pharmaceuticals, and Teva Pharmaceutical. According to TipRanks, Gerberry has an average return of 16.0% and a 61.11% success rate on recommended stocks.
In another report released on March 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.